Market Overview:
The global rabies vaccine for humans market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of rabies, increasing awareness about the benefits of vaccination, and technological advancements in the field of rabies vaccines. However, lack of awareness about rabies and its prevention among people in developing countries is a major challenge for the growth of this market. The global rabies vaccine for humans market can be segmented on the basis of type into preventative vaccines and emergency vaccines. The preventative vaccine segment is further sub-segmented into monovalent vaccines and multivalent vaccines. The emergency vaccine segment is further sub-segmented into human diploid cell culture (HDCV) basedvaccinesand purified chick embryo cell (PCEV) basedvaccines .Onthe basisofapplication,themarketcanbe dividedinto pre-exposure prophylaxis (PEP) and post-exposure prophylaxis(PEP). Pre-exposure prophylaxis protects people who have not been exposed to Rabies virus before from getting infected with it while post exposure prophylaxis helps protect people who have been exposed to Rabies virus from getting infected with it .
Product Definition:
A vaccine used to prevent rabies in humans. Rabies is a viral disease that can be fatal if not treated. The vaccine helps the body build immunity to the virus. It is given as a series of shots, usually starting before exposure to the virus and continuing for a few weeks or months afterwards.
Preventative Vaccine:
Preventative vaccines are those that provide immunization against a disease before the occurrence of an infection. They act as prophylactic or preventative measures to avoid the development of the disease. Preventive vaccine is used in animals too, but it’s mostly used for humans since they can communicate diseases to each other through physical contact and transmission through saliva or blood is more easily observed and prevented using preventive vaccines rather than curative ones.
Emergency Rabies Vaccine:
Emergency rabies vaccine is a human diploid cell vaccine developed in laboratories. It's usage was first approved by the U.S. FDA in 1970 and since then it has been used extensively across the globe to control canine rabies infection, which is now considered as a significant public health problem due to growing number of dogs as well as cats being infected with Lyssaviruses worldwide.
Application Insights:
On the basis of application, the global market is segmented into pre-exposure prophylaxis, post-exposure prophylaxis and others. The pre-exposure prophylaxis segment held a major share in 2017 due to high usage rates of rabies vaccines for humans across countries such as India and China. In addition, factors such as increasing number of travelers from India to Africa and Asia Pacific region for business or tourism purposes coupled with low awareness about prevention against rabies are expected to boost demand over the forecast period.
The post exposure prophylaxis (PEP) vaccine is used in cases where individuals have been exposed to rabid animals or animal fluids/ tissues since it provides immediate protection against infection after exposure by preventing virus entry into cells via antibody response.
Regional Analysis:
North America dominated the global market in 2017, with a revenue share of over 60.0%. This is due to the presence of well-established healthcare infrastructure and high animal population. The U.S., being a developed nation, has an abundant supply of rabies vaccine for both preventive and post-exposure purposes, which aids in maintaining its dominance in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing incidence rates of rabid animals and human infections across various countries such as India, China, Indonesia etc.; thus leading to an increase demand for post-exposure prophylaxis vaccines during this period.
Growth Factors:
- Increasing incidence of rabies across the globe
- Growing awareness about the benefits of rabies vaccine among people
- Rising demand for safe and effective vaccines against rabies
- Technological advancements in the field of rabies vaccine development
- Availability of government funding for research and development on rabies vaccine
Scope Of The Report
Report Attributes
Report Details
Report Title
Rabies Vaccine for Humans Market Research Report
By Type
Preventative Vaccine, Emergency Rabies Vaccine
By Application
Pre-exposure prophylaxis, Post-exposure prophylaxis
By Companies
Novartis, Sanofi, GlaxoSmithKline, Merck, Chengda, Yisheng, Prcmise, VACN, Changsheng, BCHT, Hissen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
185
Number of Tables & Figures
130
Customization Available
Yes, the report can be customized as per your need.
Global Rabies Vaccine for Humans Market Report Segments:
The global Rabies Vaccine for Humans market is segmented on the basis of:
Types
Preventative Vaccine, Emergency Rabies Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pre-exposure prophylaxis, Post-exposure prophylaxis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Sanofi
- GlaxoSmithKline
- Merck
- Chengda
- Yisheng
- Prcmise
- VACN
- Changsheng
- BCHT
- Hissen
Highlights of The Rabies Vaccine for Humans Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Preventative Vaccine
- Emergency Rabies Vaccine
- By Application:
- Pre-exposure prophylaxis
- Post-exposure prophylaxis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rabies Vaccine for Humans Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rabies vaccine is a vaccine that helps protect humans from rabies. Rabies is a serious viral disease that can be deadly if not treated quickly. Rabies vaccines help prevent people from getting rabies, which can save their lives.
Some of the major companies in the rabies vaccine for humans market are Novartis, Sanofi, GlaxoSmithKline, Merck, Chengda, Yisheng, Prcmise, VACN, Changsheng, BCHT, Hissen.
The rabies vaccine for humans market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Rabies Vaccine for Humans Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Rabies Vaccine for Humans Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Rabies Vaccine for Humans Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Rabies Vaccine for Humans Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Rabies Vaccine for Humans Market Size & Forecast, 2018-2028
4.5.1 Rabies Vaccine for Humans Market Size and Y-o-Y Growth
4.5.2 Rabies Vaccine for Humans Market Absolute $ Opportunity
Chapter 5 Global Rabies Vaccine for Humans Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Rabies Vaccine for Humans Market Size Forecast by Type
5.2.1 Preventative Vaccine
5.2.2 Emergency Rabies Vaccine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Rabies Vaccine for Humans Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Rabies Vaccine for Humans Market Size Forecast by Applications
6.2.1 Pre-exposure prophylaxis
6.2.2 Post-exposure prophylaxis
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Rabies Vaccine for Humans Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Rabies Vaccine for Humans Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Rabies Vaccine for Humans Analysis and Forecast
9.1 Introduction
9.2 North America Rabies Vaccine for Humans Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Rabies Vaccine for Humans Market Size Forecast by Type
9.6.1 Preventative Vaccine
9.6.2 Emergency Rabies Vaccine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Rabies Vaccine for Humans Market Size Forecast by Applications
9.10.1 Pre-exposure prophylaxis
9.10.2 Post-exposure prophylaxis
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Rabies Vaccine for Humans Analysis and Forecast
10.1 Introduction
10.2 Europe Rabies Vaccine for Humans Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Rabies Vaccine for Humans Market Size Forecast by Type
10.6.1 Preventative Vaccine
10.6.2 Emergency Rabies Vaccine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Rabies Vaccine for Humans Market Size Forecast by Applications
10.10.1 Pre-exposure prophylaxis
10.10.2 Post-exposure prophylaxis
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Rabies Vaccine for Humans Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Rabies Vaccine for Humans Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Rabies Vaccine for Humans Market Size Forecast by Type
11.6.1 Preventative Vaccine
11.6.2 Emergency Rabies Vaccine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Rabies Vaccine for Humans Market Size Forecast by Applications
11.10.1 Pre-exposure prophylaxis
11.10.2 Post-exposure prophylaxis
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Rabies Vaccine for Humans Analysis and Forecast
12.1 Introduction
12.2 Latin America Rabies Vaccine for Humans Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Rabies Vaccine for Humans Market Size Forecast by Type
12.6.1 Preventative Vaccine
12.6.2 Emergency Rabies Vaccine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Rabies Vaccine for Humans Market Size Forecast by Applications
12.10.1 Pre-exposure prophylaxis
12.10.2 Post-exposure prophylaxis
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Rabies Vaccine for Humans Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Rabies Vaccine for Humans Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Rabies Vaccine for Humans Market Size Forecast by Type
13.6.1 Preventative Vaccine
13.6.2 Emergency Rabies Vaccine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Rabies Vaccine for Humans Market Size Forecast by Applications
13.10.1 Pre-exposure prophylaxis
13.10.2 Post-exposure prophylaxis
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Rabies Vaccine for Humans Market: Competitive Dashboard
14.2 Global Rabies Vaccine for Humans Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Sanofi
14.3.3 GlaxoSmithKline
14.3.4 Merck
14.3.5 Chengda
14.3.6 Yisheng
14.3.7 Prcmise
14.3.8 VACN
14.3.9 Changsheng
14.3.10 BCHT
14.3.11 Hissen
